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Abstract
Background: Malaria remains a global public health challenge. It is widely believed that an effective vaccine
against malaria will need to incorporate multiple antigens from the various stages of the parasite’s complex life
cycle. Plasmodium falciparum Merozoite Surface Protein 4 (MSP4) is a vaccine candidate that has been selected for
development for inclusion in an asexual stage subunit vaccine against malaria.
Methods: Nine monoclonal antibodies (Mabs) were produced against Escherichia coli-expressed recombinant MSP4
protein and characterized. These Mabs were used to develop an MSP4-specific competition ELISA to test the
binding specificity of antibodies present in sera from naturally P. falciparum-infected individuals from a malaria
endemic region of Vietnam. The Mabs were also tested for their capacity to induce P. falciparum growth inhibition
in vitro and compared against polyclonal rabbit serum raised against recombinant MSP4
Results: All Mabs reacted with native parasite protein and collectively recognized at least six epitopes. Four of
these Mabs recognize reduction-sensitive epitopes within the epidermal growth factor-like domain found near the
C-terminus of MSP4. These sera were shown to contain antibodies capable of inhibiting the binding of the six
Mabs indicating infection-acquired responses to the six different epitopes of MSP4. All of the six epitopes were
readily recognized by human immune sera. Competition ELISA titres varied from 20 to 640, reflecting
heterogeneity in the intensity of the humoral response against the protein among different individuals. The IgG
responses during acute and convalescent phases of infection were higher to epitopes in the central region than to
other parts of MSP4. Immunization with full length MSP4 in Freund’s adjuvant induced rabbit polyclonal antisera
able to inhibit parasite growth in vitro in a manner proportionate to the antibody titre. By contrast, polyclonal
antisera raised to individual recombinant fragments rMSP4A, rMSP4B, rMSP4C and rMSP4D gave negligible
inhibition. Similarly, murine Mabs alone or in combination did not inhibit parasite growth.
Conclusions: The panel of MSP4-specific Mabs produced were found to recognize six distinct epitopes that are
also targeted by human antibodies during natural malaria infection. Antibodies directed to more than three
epitope regions spread across MSP4 are likely to be required for P. falciparum growth inhibition in vitro.
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Malaria infections of humans, particularly that due to
Plasmodium falciparum continues to be a major cause
of morbidity and mortality in tropical countries. There
is an urgent need for the development of efficacious
control measures, one component of which could be a
safe, effective and affordable malaria vaccine against P.
falciparum. It is widely believed that any such vaccine
will need to incorporate multiple antigens from the var-
ious stages of the parasite’s complex life cycle [1].
The surface of the asexual stage merozoite form of P.
falciparum is composed of a number of proteins that are
the targets of immune attack by antibodies. One of these
proteins is Merozoite Surface Protein 4 (MSP4), a rela-
tively abundant glycosylphosphatidylinositol-anchored
protein that contains a single epidermal growth factor
(EGF)-like domain adjacent to the carboxyl terminus of
the protein [2,3]. Although the function of MSP4 is not
known, the msp4 gene is refractory to genetic deletion
and it is thus thought to be essential for parasite replica-
tion in in vitro culture and presumably also in the human
bloodstream [4]. Several features of MSP4 make it an
attractive vaccine candidate. Firstly, MSP4 is exposed on
the merozoite surface making it available for antibody
binding and anti-MSP4 antibodies are readily detected in
people living in malaria endemic regions [5,6] suggesting
a possible role for these antibodies in human immunity
to malaria. Secondly, MSP4 shows a high degree of con-
servation among P. falciparum isolates [7-9] minimizing
the possibility of immune evasion secondary to strain-
specific antibody responses. Thirdly, immunization of
mice with recombinant Plasmodium yoelii MSP4/5, a
homologue of both MSP4 and the related antigen MSP5,
protects mice against lethal parasite challenge [10,11].
Protection is enhanced when MSP4/5 is immunized in
combination with P. yoelii MSP119 [12] suggesting that it
would be an attractive addition to a multi-antigen vac-
cine containing MSP119.
A panel of nine anti-MSP4 monoclonal antibodies
(Mabs) that recognize distinct epitopes of the antigen
were produced and characterized. These antibodies were
tested in a competition enzyme-linked immunosorbent
assay (ELISA) against human immune sera collected
from P. falciparum-infected subjects to analyse the
binding characteristics of anti-MSP4 antibodies induced
by natural infection. The ability of polyclonal and mono-
clonal anti-MSP4 antibodies to inhibit parasite growth
in vitro were also assessed in this study.
Methods
Production of antigens
Parasite proteins
Plasmodium falciparum isolate 3D7 was cultured in
vitro as previously described [3] and total parasite
protein preparations were obtained by saponin lysis of
parasites as previously described [5].
Recombinant proteins
Full-length MSP4 consisting of amino acid residues 21-
248 was expressed in E. coli as a recombinant hexahisti-
dine tagged protein (rMSP4) or as a GST fusion protein
(rMSP4
GST) as described [5] and also expressed in Sac-
charomyces cerevisiae (rMSP4
Sc) as described [13]. The
protein, rMSP4, was used to immunize mice and in
ELISA as a target antigen. In order to map the epitopes
corresponding to different regions of the MSP4 protein,
four previously described glutathione S-transferase
(GST) recombinant fusion proteins designated rMSP4A,
rMSP4B, rMSP4C and rMSP4D were produced [5].
Each fragment represents approximately one quarter of
the mature MSP4 protein (MSP4A corresponding to
amino acids 21-83; MSP4B to amino acids 84-147;
MSP4C to amino acids 148-203 and MSP4D to amino
acids 204-248) (Figure 1). The rMSP119 was a kind gift
from Paul Gilson (WEHI, Melbourne).
MSP4 synthetic peptides
Overlapping peptides spanning the entire length of the
MSP4 molecule were synthesized by Auspep Pty Ltd.
(Melbourne, Australia). All peptides were 20 amino
acids in length and each adjacent peptide overlapped by
10 amino acids (Figure 1).
Human and animal polyclonal antibodies
Human immune sera were collected from residents liv-
ing in Khanh Hoa province in south central Vietnam.
Initial blood samples were obtained from volunteers in
June 1994 (designated T0). These individuals were thor-
oughly treated with quinine sulphate, doxycycline
cyclate and primaquine phosphate then monitored for a
period of 6 months [6]. Additional blood samples (T1)
were collected from those individuals who had positive
smears during the 6-month period. They were treated
with mefloquine (15 mg/kg) and a third sample (T28)
was collected 28 days later. No volunteers had recurrent
parasitaemia during the 28 days of follow-up after
mefloquine treatment. A panel of individual serum sam-
ples were obtained from 30 healthy Australian blood
donors and pooled for use as negative control sera.
None of these donors had a history of exposure to
malaria.
Rabbit antisera to rMSP4, rMSP4A, rMSP4B, rMSP4C,
rMSP4D, rMSP4
GST,r M S P 4
Sc and MSP119 were pro-
duced in New Zealand White rabbits using Freund’s
adjuvants as previously described [5]. Rabbit anti-AMA-
1 as purified IgG was a kind gift from Carole Long
(NIH, USA).
Production of Mabs
Briefly, BALB/c mice were immunized intraperitoneally
with 25 μg of rMSP4 protein in Freund’s complete adju-
vant, followed by two further injections of 25 μg protein
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Serum was tested after the final immunization by ELISA
for the presence of anti-MSP4 antibodies. A final boost
of 25 μg protein in PBS was given and three days later
the mice were killed and spleen cells fused with SP2
myeloma cells and hybridomas selected as described
previously [14]. Anti-MSP4 antibodies were screened for
reactivity to the immunizing antigen by ELISA. Reactiv-
ity to native protein was also assessed by immunoblot-
ting 3D7 extracts and by indirect immunofluorescence
assay (IFA) to fixed merozoites [15]. Monoclonality was
ensured by limiting dilution twice and further testing as
described above. Selected clones were expanded by
growth in RPMI medium containing 10% (v/v) bovine
calf serum. The IgG subclass of each Mab was deter-
mined by ELISA using an isotype determination kit
(Sigma Poole, UK). Mabs were purified from hybridoma
supernatant using G-Sepharose 4 protein purification
columns (Pharmacia Biotech, Victoria, Australia) and
biotinylation of Mabs was carried out using Sulfo-NHS-
Biotin (Pierce Biotechnology) according to the manufac-
turer’s recommendations.
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Figure 1 Location of Mab epitopes within the MSP4 amino acid sequence. Full amino acid sequence of MSP4 (blue) is aligned with the
sequences corresponding to four recombinant fragments (MSP4A: amino acids D21-E83; MSP4B: A84-E147: MSP4C: A148-D203; MSP4D: L204-S248), and
23 synthetic peptides (MSP4.1 - MSP4.23). The epitopes for a number of Mabs are indicated in red within several of the peptides: Mab H12
(MSP4.2), Mab 6G10 (MSP4.13), and Mabs 4C10, 1G10, 1H2, 6G11 (MSP4.20).
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Parasite extracts or recombinant MSP4 were resolved on
12% (v/v) polyacrylamide gels by SDS-PAGE under non-
reduced, reduced, or reduceda n da l k y l a t e dc o n d i t i o n s
and transferred to PVDF membrane for immunoblotting
as described previously [5]. Primary anti-MSP4 Mab
binding was detected with anti-mouse immunoglobulin
conjugated to horseradish peroxidase (Silenus Labora-
tories, Melbourne, Australia) and developed using the
Renaissance Chemiluminescence Reagent (NEN Life
Science Products, Boston, Mass., USA).
Indirect ELISA
All procedures were carried out as described previously
[5] with minor modifications. Briefly, 96 well microtiter
plates (Immulon 2; Dynatech Laboratories, Chantilly
Va.) were coated with recombinant MSP4 (1 μg/mL) or
synthetic peptides (10 μg / m L )a t4 ° Co v e r n i g h t ,w a s h e d
with PBS/0.5% (v/v) Tween 20 (PBST) and blocked with
5% (w/v) skim milk powder in PBST. Mabs were added
in duplicate wells. Primary antibody was detected with
alkaline-phosphatase conjugated goat anti-mouse immu-
noglobulin (Silenus Laboratories, Melbourne, Australia)
followed by development with p-nitrophenyl phosphate
(Sigma). The optical density (OD) was read at 405 nm.
Each sample was tested against PBS or RPMI medium
as a background control. Specific reactivity against
MSP4 protein was obtained by subtracting the average
OD of the control wells from the average OD obtained
for wells coated with antigen.
Competition ELISA with biotinylated Mabs
Microtiter plates were coated with rMSP4D and other
steps performed as described previously [16]. Briefly,
unlabelled Mab was added and incubated for one hour
at 37°C followed by washing and addition of the biotiny-
lated Mab at a concentration predetermined by titration
and incubated as above. After washing, Streptavidin-
HRP conjugate (50 μL/well; Pierce Biotechnology) was
added and incubated as above, followed by development
with o-phenylenediamine substrate (75 μL/well; Sigma).
The colour reaction was stopped by addition of 50 μL
of 1 M sulfuric acid and the absorbance was read at 490
nm. The degree of inhibition for each antibody was cal-
culated using the following equation: I (%) = [(ODL -
ODU+L)/ ODL] × 100, where I = inhibition (%); ODL =
OD405 of the labelled antibody alone and ODU+L =
OD405 of the labelled antibody where unlabelled anti-
body had been added.
Competition ELISA with human serum
Microtiter plates were coated with rMSP4B, rMSP4C or
rMSP4D, blocked as above and antigen reacted with
serial two-fold dilutions of human sera as described pre-
viously [17]. After washing, 50 μL/well of each anti-
MSP4 Mab was added and incubated for two hours at
37°C. All other steps were as described for indirect
ELISA. Serum samples were tested against PBS as a
negative control. The competition titres were defined as
the dilutions of the test sera that resulted in equal or
higher OD405 values as the mean plus the standard
deviations (2SD) of the OD405 values of the 30 negative
control sera. Sera with a titre ≥ 20 were considered
positive. The percentage inhibition of each serum at 1/
10 dilution was calculated using the following equation:
I (%) = [(ODIFS -O D TS)/ ODIFS] × 100, where I = inhi-
bition (%); ODIFS =O D 405 of the inhibitor-free sample
and ODTS =O D 405 of the test sample. The antibody
levels between sera at different time points were com-
pared using the two-tailed Wilcoxon matched-pairs
ranked sign test. To compare the prevalence of antibody
inhibition between different groups of subjects, the two-
tailed Mann-Whitney test was used.
ELISA for affinity measurement
A relative affinity assay (potassium thiocyanate inhibi-
tion) was performed according to a technique described
previously [18]. Briefly, microtiter plates were coated
and blocked as above. Mabs were added and incubated
at 37°C for two hours. After washing, graded concentra-
tions of potassium thiocyanate (KSCN) were added (100
μL/well) in 0.25 mol/L increments with an endpoint
concentration of 6 mol/L and incubated for 15 mins at
room temperature. All subsequent steps were performed
as described for the indirect ELISA. The raw data was
plotted to demonstrate a linear relationship between
KSCN concentration and antibody-antigen interaction.
T h em o l a r i t yo fK S C Nt h a tw o u l dp r o d u c ea5 0 %
decrease in the calculated maximum OD provides a
value for the relative antibody affinity. The greater the
molarity required, the greater the relative affinity.
Parasite growth inhibition assay
The in vitro growth inhibition of P. falciparum was
assayed as previously described [19] with modifications.
Parasites were synchronized by sorbitol lysis twice at a
four hour interval to obtain ring stages and allowed to
mature to the late trophozoite/schizont stage in the next
24 hours. Synchronously growing parasites were diluted
with fresh red blood cells (RBCs) and cultured in 96-
well plates at 1% parasitaemia and 1% haematocrit in a
total volume of 100 μL, in the presence of anti-MSP4
polyclonal rabbit serum or mouse-derived Mabs. Each
serum or Mab sample was tested in triplicate at a final
concentration of 20-30% and 250 μg/mL respectively.
All sera were heat inactivated at 56°C for 30 mins prior
to testing to destroy complement activity, then pre-
adsorbed against uninfected RBC (O
+)t or e m o v ea n y
anti-human RBC antibodies. Pre-immune serum was
included as a background control. After culture for 40-
44 hours, mature-stage parasites were harvested, fixed
with 0.025% glutaraldehyde and stained with 10 μg/mL
propidium iodide (PI). Fifty thousand cells from each
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son) using 488 nm laser for excitation and 670 nm for
emission. Uninfected RBCs stained with PI were used as
a negative control and the cut-off was set at 0.05%. The
parasitaemia of each sample was calculated using CXP
analysis software (Becton Dickinson). The percentage of
parasite growth inhibition was calculated according to
the equation GI (%) = [(PC -P T)/ PC] × 100, where GI
= growth inhibition (%); PC = parasitaemia in control
and PT = parasitaemia in presence of test antibody (rab-
bit polyclonal sera or Mab). Differences between the test
and control cultures were assessed using the two-tailed
student t test.
Results
Generation and characterization of anti-MSP4 Mabs
A panel of nine MSP4-specific Mabs was generated and
characterized (Table 1). The specificity of the Mabs was
confirmed by ELISA against rMSP4. Positive recognition
of trophozoite and schizont stages of P. falciparum
using indirect IFA further supported the specificity of
the Mabs. In addition, all nine Mabs recognized a pro-
tein resolving at approximately 40 kDa when immuno-
blotted against blood stage P. falciparum lysates
consistent with that previously observed for MSP4. The
sequence of MSP4 suggests that the theoretical molecu-
lar weight of this protein is 27 kDa, but has previously
been reported to show aberrantly slow electrophoretic
migration, resolving at 40-45 kDa by SDS-PAGE [2].
T h ea n t i b o d yi s o t y p eo fa l ln i n eM a b sw a sI g G 1 as
determined by an isotype specific ELISA.
Initial epitope recognition was carried out by immu-
noblotting each Mab against the recombinant MSP4
fragment proteins rMSP4A, rMSP4B, rMSP4C and
rMSP4D (Table 1). Each fragment corresponds to
approximately one quarter of the mature MSP4 protein.
Mab H12 recognized the N-terminal quarter of the pro-
tein represented by fragment rMSP4A, Mab 1B7 bound
to rMSP4B and Mab 6G10 bound to rMSP4C, both
representing the central region of MSP4. The remaining
six Mabs 4C10, 1G10, 8G3, 1H2, 7F4, and 6G11 bound
to rMSP4D, indicating recognition of epitopes in the C-
terminal region of MSP4 which includes the EGF-like
domain.
The reduction sensitivity of epitopes was examined in
more detail by reacting each of the Mabs against rMSP4
that was either non-reduced or reduced and alkylated
prior to SDS-PAGE. This treatment destroys conforma-
tional epitopes that require disulfide bonds for their
integrity. The MSP4D region contains three such bonds
(Figure 2). The binding abilities of Mabs 1B7 and 6G10,
which recognize the central regions of MSP4, were not
affected by the loss of conformational epitopes suggest-
ing that these Mabs recognize linear epitopes of MSP4.
Interestingly, Mab H12 only recognized reduced rMSP4,
suggesting that the original rMSP4 immunogen may
have been partially denatured. The epitopes of the C-
terminal region were examined by testing each of the
rMSP4D-positive Mabs against both rMSP4 and
rMSP4D as non-reduced or reduced and alkylated pro-
teins. Binding of Mabs 4C10, 1G10, 7F4 and 8G3 was
abolished when reacted with reduced and alkylated pro-
teins. The same results were observed with these Mabs
when reacted with either reduced or reduced and alky-
lated parasite lysates. These observations indicate that
these Mabs are directed to conformational epitopes that
are dependent on disulphide bond formation. The bind-
ing abilities of Mabs 6G11 and 1H2 were not affected
by reduction of the target epitopes indicating that they
recognize linear epitopes within the C-terminus of
MSP4.
The affinity of the Mabs was determined by the ability
of thiocyanate to interfere with antigen-antibody binding
in a concentration dependent manner, and are shown in
Table 1. The relative affinity of the Mabs ranged from
1.1 (1H2) to 2.2 (1B7).
Epitope mapping of anti-MSP4 Mabs
To further define the epitopes of the C-terminal region
of MSP4, the ability of the six anti-MSP4D Mabs to
block each other’s binding to rMSP4D was assessed
using competition ELISA (Table 2). Binding of Mab
4C10 and 1G10 to rMSP4D were completely blocked by
each other. Similarly, Mabs 7F4 and 8G3 showed com-
petitive binding. This indicates that the 4C10/1G10 and
8G3/7F4 Mab pairs recognize identical or highly over-
lapping epitopes. Mab 1H2 competed with Mabs 4C10/
1G10 and 6G11 for binding to rMSP4D, but not with
8G3/7F4, whereas Mabs 4C10/1G10 were shown to
compete with 6G11. The epitopes for Mabs 1H2, 4C10/
Table 1 Properties of MSP4-specific Mabs
Mab Isotype
a Recognition
b Reduction Relative
Fragment Peptide Sensitivity
c Affinity
d
H12 IgG1 rMSP4A MSP4.2 * ND
1B7 IgG1 rMSP4B none - 2.2
6G10 IgG1 rMSP4C MSP4.13 - 2.1
4C10 IgG1 rMSP4D MSP4.20 + 1.7
1G10 IgG1 rMSP4D MSP4.20 + 1.7
7F4 IgG1 rMSP4D none + 1.4
8G3 IgG1 rMSP4D none + 1.4
1H2 IgG1 rMSP4D MSP4.20 - 1.1
6G11 IgG1 rMSP4D MSP4.20 - 1.6
a) Antibody isotype by ELISA. b) Fragment specificity by immunoblotting and
ELISA and peptide recognition by ELISA. c) Reduction sensitivity measured as
lack of reactivity (+) to reduced or reduced and alkylated MSP4. *mAb H12
only recognized reduced MSP4. d) Antibody affinity determined by ability of
thiocyanate to interfere with antigen-antibody binding. ND: not determined.
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other but individually they are distinct as 6G11 and 1H2
are directed to linear epitopes whereas 4C10 and 1G10
recognize a conformational epitope (Table 1). Mabs
8G3/7F4 recognize a separate, distinct conformational
epitope.
Overlapping synthetic peptides spanning the entire
length of the MSP4 molecule were used in an ELISA to
further map Mab recognition sites to 20-amino acid lin-
ear epitopes (Figure 1). Mab H12, which only recognized
reduced rMSP4 and rMSP4A, mapped to the N-terminal
peptide MSP4.2. Mab 1B7, which recognizes a reduc-
tion-insensitive epitope within rMSP4B did not bind to
any of the peptides. Mab 6G10, which targets a reduc-
tion-insensitive epitope in rMSP4C, was shown to bind
to peptide MSP4.13. This peptide spans the junction of
the MSP4B and MSP4C regions with seven residues in
the B region and thirteen residues in the C region. As
this Mab recognized rMSP4C but not rMSP4B it was
possible to further map this epitope to the thirteen resi-
d u es e q u e n c eA I P K K V V Q P S S S N( u n d e r l i n e di nF i g u r e
1) which lies within the MSP4C region. Epitope map-
ping using peptides spanning the MSP4D region con-
taining the EGF-like domain was also performed. Mabs
7F4 and 8G3 did not show detectable binding to any of
the synthetic peptides, consistent with the conforma-
tional nature of the epitope they recognize. Mabs 1H2
and 6G11, which recognize reduction-insensitive linear
epitopes, bound to peptide MSP4.20. Surprisingly, Mabs
4C10 and 1G10, which recognize reduction-sensitive
e p i t o p e s ,w e r ea l s oa b l et ob i n dt op e p t i d eM S P 4 . 2 0 .
This suggests that their epitopes are either partially lin-
ear, or that two of the three cysteines within this pep-
tide are producing a conformation that at least partly
forms the epitope for 4C10 and 1G10. The 3D structure
of the EGF-like domain of some Plasmodium merozoite
surface proteins, such as that of Plasmodium vivax Mer-
ozoite Surface Protein 1 (PvMSP1) have been resolved
[20]. According to the published 3D structure of
PvMSP1, the pairing of the disulphide bonds occurs
between C1-C3, C2-C4, and C5-C6 (Figure 2). BLAST
was used to align the predicted location of the sequence
analogous to peptide MSP4.20 in the PvMSP1 EGF
domain and is shown in Figure 2. Peptide MSP4.20 con-
tains cysteines C2, C3 and C4 and therefore this area is
involved in the formation of two disulphide bonds,
being C1-C3 and C2-C4. It is concluded that the con-
formational epitope recognized by Mabs 4C10 and 1G10
is likely to involve the disulphide bond formed between
C2 and C4.
Naturally acquired human antibodies compete with anti-
MSP4 Mabs
It was of interest to determine whether antibodies
induced during natural infection of humans recognized
N
C
C1
C2
C3 C4
C5
C6
N
C
Figure 2 Cartoon of the structure of the EGF domain from Plasmodium vivax Merozoite Surface Protein-1. Disulphide bonds are
highlighted in yellow. The sequence analogous to peptide MSP4.20 (alignment performed using BLAST) in the MSP4 EGF domain is highlighted
in cyan. The figure was prepared by James Whisstock using PYMOL (DeLanoScientific LLC.)
Table 2 Mapping of Overlapping Epitopes of the MSP4
EGF-like Domain
Competitor Competition for Binding with Biotinylated Mab
Mab 4C10 1G10 7F4 8G3 1H2 6G11
4C10 + +---+
1G10 + + ---+
7F4 - - + +- -
8G3 - - + + --
1H2 + + - - + +
6G11 - - - - - +
Mabs specific for rMSP4D analysed by pairwise competition ELISA.
Inhibition (+) or no inhibition (-) of binding was observed.
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recombinant MSP4. Human sera were sampled from
individuals who had demonstrable P. falciparum parasi-
taemia. Sera were collected at three different time
points: T0 a tt h eb e g i n n i n go ft h es u r v e ya n dp r i o rt o
drug treatment, T1 at the time of re-infection and drug
treatment and T28 collected from the same individuals
28 days later. The four regions of MSP4 represented by
rMSP4A, rMSP4B, rMSP4C and rMSP4D were recog-
nized by the sera from these individuals suggesting that
the human immune response to MSP4 is directed to at
least four distinct epitopes [6,7].
The ability of naturally acquired antibodies in human
immune sera to block the binding of selected MSP4
Mabs was tested in a competition ELISA. A total of 84
immune sera were examined. Initially, Mabs directed
against conformational (4C10 and 8G3) and linear (1H2
and 6G11) epitopes within rMSP4D were tested in the
presence of human serum collected at the beginning of
t h es u r v e y( T 0) .Ap o o lo fh u m a ns e r aw e r ea b l et o
block the binding of all four Mabs in a dose-dependent
manner, indicating that C-terminal conformational and
linear MSP4 epitopes are recognized by both the Mabs
and the human immune sera (Figure 3a). The data
shows that there is considerable variation between indi-
viduals in the ability of their serum antibodies to block
the binding of Mabs to MSP4 (Figure 3b). The IgG
responses at the beginning of the survey (T0), during
infection (T1) and convalescent phase (T28) of infection
were examined in competition with Mabs recognizing
epitopes within the central (MSP4C/D) and C-terminal
(MSP4D) regions of MSP4 (Figure 3b). IgG responses at
each time point were directed towards all three of the
regions tested. Serum titres varied between 1/20 and 1/
640, showing considerable variation between individuals.
The average percentage inhibition of sera from each
patient remained relatively constant before and during
infection and through convalescence.
Polyclonal anti-MSP4 antibodies inhibit in vitro parasite
growth
Rabbit polyclonal antisera raised against full-length
rMSP4 inhibit parasite growth in vitro to a moderate
but significant level (Table 3). Of the five antisera gener-
ated against rMSP4, three showed growth inhibition that
was above 40%. These antisera also showed higher anti-
rMSP4 titres with S1619 at 1 × 10
5, whereas S1621 and
S1622 (the antisera raised against S. cerevisiae-expressed
protein) showed a titre of over 1 × 10
6. The other two
antisera raised against full length rMSP4 (S193 and
S1620) had an antibody titre of 3 × 10
4 a n ds h o w e dn o
detectable growth inhibition. These results suggest a
positive correlation between the in vitro growth inhibi-
tory capacity of antisera and antibody titre. The growth
inhibitory capacity of antisera raised against fragments
of the MSP4 molecule was also examined. In contrast to
full-length protein, antisera raised against fragments
rMSP4A, rMSP4B, rMSP4C and rMSP4D gave negligible
parasite growth inhibition in vitro. This suggests that
multiple MSP4 epitopes spanning the entire protein
need to be targeted in order to significantly inhibit para-
site growth in vitro. These results were consistent with
those obtained using individual anti-MSP4 Mabs to
inhibit parasite growth. The extent of growth inhibition
obtained with the purified Mabs was not significant. To
determine if three antibody specificities in three differ-
ent fragments would be able to demonstrate inhibition,
Mabs 6G10 (anti-MSP4C), 1B7 (anti-MSP4B) and 4C10
(anti-MSP4D) were tested in combination. Significant
growth inhibition was not obtained by this combination
of antibodies. This suggests that antibodies directed to
more than such three epitopes spread across the mole-
cule are necessary to result in parasite growth inhibition.
Discussion
The natural immune response to malaria is highly com-
plex involving both antibodies and cell mediated immu-
nity [21]. The clinical symptoms of malaria are caused
by the asexual blood stage. Antibodies are particularly
important in protective immunity during this stage as
they can bind to antigens on free merozoites and inhibit
erythrocyte invasion either directly or in association
with cells to limit disease pathogenesis and clinical
symptoms. Evidence for the protective role of antibodies
in clinical malaria are provided from studies where pas-
sive transfer of antibodies from immune adults was able
to successfully treat children with severe P. falciparum
infection [22]. However, the finding that long-term
exposure to the parasite resulting in multiple antibody
specificities is necessary to generate protection from
malaria indicates that the establishment of protective
antibodies is a complex process. The breadth and mag-
nitude of the antibody responses to multiple merozoite
antigens are shown to be associated with protection
f r o mc l i n i c a lm a l a r i a[ 2 3 ] .T h ea n t i b o d yr e s p o n s et o
merozoite surface protein 1 (MSP1) has been extensively
studied and particular areas of the protein have been
found to be immuno-dominant [17]. For example, anti-
bodies against the 19 kDa C-terminal fragment of MSP1
are the major component of the invasion inhibitory
response in humans immune to malaria [19,24]. The
protective effect of these anti-MSP119 antibodies is
further dependent on their fine specificity, rather than
mere prevalence or titre [25]. Similar studies suggest the
existence of immune-dominant functional domains that
are the target of protective antibodies to apical mem-
brane antigen-1 (AMA-1) [26,27]. In contrast, our pre-
vious immuno-epidemiological studies showing
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Figure 3 Competition of naturally acquired human antibodies with anti-MSP4 specific Mabs. Serum samples were collected from
individuals who acquired and were treated for P. falciparum parasitaemia at different time points; T0, at the time of infection; T1 and T28, day 1
and day 28 following infection. a) Inhibition of Mab binding to MSP4 by a pool of human sera from infected individuals. A pool of human sera
collected at the time of infection (T0) were reacted with MSP4 by ELISA followed by addition of four Mabs (specific for the EGF like domain of
MSP4) to determine the ability of human sera to inhibit the binding of Mabs. The human serum pool was able to inhibit Mab binding in a dose-
dependent manner. The serum dilution is shown on the X axis and Absorbance value is shown on the Y axis. b) Heterogeneity of the human
MSP4-specific antibody response. Human sera collected at different time points (T0,T 1 and T28) were competed with Mabs raised to different
regions of MSP4 in the competition ELISA assay. Bars indicate the average percentage inhibition (%) at 1/10 dilution of 10 samples of human
sera tested at each timepoint and the error bars indicate standard deviation within the sample. The P values (Wilcoxon test) between the
inhibition in the matched pairs of serum samples at the different timepoints are shown.
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fine mapping and functional studies presented herein,
suggest the possibility that acquisition of protective anti-
body immunity to MSP4 could be a cumulative process
with a requirement for the generation of multiple anti-
body specificities.
In this study, nine monoclonal antibodies specific for
recombinant MSP4 protein expressed in Escherichia coli
were produced and characterized. These Mabs recognize
six distinct epitopes of MSP4, including two conforma-
tional epitopes in the C-terminal region containing the
EGF-like domain. The remaining Mabs recognize epi-
topes that are not affected by reduction and alkylation
and are presumably linear, with two in the C-terminal
region of MSP4 and two in the central region of the
protein. The reactivity of Mab H12 was interesting in
that it reacted only with the reduced and alkylated form
of full-length MSP4 but mapped to a region of the
molecule, MSP4A, that has no disulphide bonds. This
suggests that there are long range conformational effects
which alter the shape of the N-terminus of MSP4 when
disulphide bonds in the C-terminus are interrupted.
This is in accord with previous observations in which
the redox state of the EGF-domain was crucial for the
antigenicity of the entire protein, including regions that
are not immediately adjacent in the primary structure
and did not contain disulphide domains such as the N-
terminus [5].
This panel of antibodies was used in competition
ELISA to analyse the binding specificities of naturally
acquired antibodies to MSP4 in individuals from a
malaria-endemic region of Vietnam. The three tested
regions of MSP4 were readily recognized by the sera
examined. The existence of persistent heterogeneity was
observed among individuals in the level of antibody
reactivity and the spread of epitope recognition. The
reactivity of anti-MSP4 antibodies in the sera tested was
considerably higher for epitopes in the central region of
MSP4, in particular the MSP4B region. This result is
also in agreement with our previous findings [6] that
the percentage of positive responses was higher for
MSP4B (92.5%) compared to the EGF-like domain con-
taining MSP4D region (71.3%). This is also in accord
with other reports where cysteine-rich regions of pro-
teins have been shown to be less immunogenic [28]. In
contrast, six of the nine Mabs generated in this study by
immunization of mice with rMSP4 were specific for the
EGF-like domain.
MSP4 is a surface exposed protein that is highly con-
served. The finding that antibodies target multiple epi-
topes spread across the entire length of the molecule
may provide some insight into the mechanisms for co-
evolution of parasite with its human host. It is possible
to speculate that the sequence conservation of MSP4
maybe partly caused by the fact that immune selective
pressure needs to target multiple epitopes simulta-
neously rather than individual epitopes. In addition to
helping in understanding the nature of the antibody
response to MSP4 during infection, the panel of mono-
clonal antibodies will also serve as valuable reagents for
testing product integrity, purity, antigenicity and immu-
nological activity during the highly complex and strin-
gently regulated process of MSP4 vaccine development
and manufacture.
It is shown that polyclonal rabbit antisera raised
against the full length MSP4 protein are able to inhibit
parasite growth in vitro. In contrast, rabbit antisera spe-
cific for MSP4 fragments corresponding to three of the
regions of MSP4 were unable to inhibit parasite growth.
Similarly, the individual Mabs had no inhibitory effect
on the growth of the parasite. These results are
Table 3 In vitro Growth-Inhibitory Activities of MSP4-
Specific Antibodies
Antibody
Reagent
Immunogen
1 Specificity
2 MSP4
Titre
3
%
GIA
4
Polyclonal Sera
S193 rMSP4
GST Full MSP4 30,000 12
S1619 rMSP4 Full MSP4 100,000 47*
S1620 rMSP4 Full MSP4 30,000 15*
S1621 rMSP4
Sc Full MSP4 1,000,000 41**
S1622 rMSP4
Sc Full MSP4 1,000,000 64**
S104 rMSP4A MSP4A ND 14
S127/162 rMSP4C MSP4C ND -26
S133 rMSP4D MSP4D ND -18
Mabs
H12 rMSP4 MSP4A 6
1B7 rMSP4 MSP4B 13
6G10 rMSP4 MSP4C 12
4C10 rMSP4 MSP4D 10
1G10 rMSP4 MSP4D 8
7F4 rMSP4 MSP4D 8
8G3 rMSP4 MSP4D 7
1H2 rMSP4 MSP4D 5
6G11 rMSP4 MSP4D 9
6G10+1B7+4C10 rMSP4 MSP4B/C/D 11
PBS control - - 5
Control Reagents
Anti-MSP119 sera 51**
Anti-AMA-1 purified IgG 88**
Anti-GST sera 10
1) Polyclonal and monoclonal antibodies were raised against recombinant
MSP4 produced in E.coli as a hexahistidine (rMSP4) or GST (rMSP4
GST, rMSP4A/
C/D) tagged protein. S1621 and S1622 were raised against S. cerevisiae-
expressed protein (rMSP4
Sc). 2) Specificity confirmed by ELISA and/or
immunoblotting. 3) Titre for selected polyclonal sera determined by ELISA
against rMSP4. 4) Parasite growth inhibition assay (GIA) results (%). Statistical
significance of inhibition by two-tailed student t-test comparing final
parasitaemias in wells with test antibody to control culture; p < 0.1 (*), p <
0.01 (**) and p > 0.1. ND: not determined.
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vivo P. yoelii murine malaria challenge model in our
laboratory. Immunizations carried out with recombinant
PyMSP4/5 were able to induce immune responses that
protect mice against challenge with a lethal dose of P.
yoelii parasites [10]. In contrast, immunizations with
PyMSP4/5 fragments did not confer protection (L. Ked-
zierski, unpublished data). One explanation for this is
that an antibody response directed to multiple epitopes
spread across the molecule is necessary for arresting
parasite growth. Since the combination of three Mabs
directed to different regions of the MSP4 molecule were
a l s ou n a b l et op r o d u c eag r o w t hi n h i b i t o r ye f f e c t ,i ti s
likely that a polyclonal antibody response to more than
three epitopes is necessary. Alternatively another possi-
bility is that antibodies directed to epitopes other that
those represented by the Mabs are required for invasion
inhibition. These epitopes maybe ones that are only pre-
sent in the complete folded sequence and accessible on
the merozoite surface. The lack of inhibitory activity
despite the high affinity binding of the Mabs may also
be related to the function and size of the MSP4 mole-
cule. In the case of AMA-1, inhibitory antibodies bind
and block epitopes that are involved in the parasite
invasion process. MSP4 is a small molecule (270 amino
acids) and of relatively low abundance on the surface of
the merozoite. Hence, the binding of antibodies to
MSP4 alone may not be sufficient to cause high levels
of parasite dysfunction or invasion inhibition, but
MSP4-specific antibodies may contribute in combination
with antibodies specific for other merozoite surface
proteins.
Following schizont rupture and merozoite release, re-
invasion occurs within seconds. Therefore, antibodies
will only be useful if they are available at very high con-
centrations and/or are of high affinity. Consistent with
this picture, the observations in this study showed that
growth inhibitory capacity is directly proportional to
antibody titre. Similar observations have been made in
field studies in malaria endemic areas; under natural
exposure, immunity to malaria results from high titre
antibodies to multiple antigenic targets [23]. These
observations provide support for the production of com-
bination blood stage vaccines.
The capacity to induce experimental antibodies with
growth inhibitory activity (GIA) in vitro is currently
being used as a criterion for selection of blood stage
antigens that are to be incorporated into a subunit
malaria vaccine. Growth inhibition in vitro is considered
af u n c t i o n a la s s a yb e c a u s ei tm e a s u r e st h ec a p a c i t yo f
antibodies to bind and inhibit parasite invasion and/or
growth. AMA-1 [27] and MSP1 [29] are the blood stage
antigens currently in the most advanced stages of being
developed as human malaria vaccines. Antibodies to
AMA-1 so far have been able to show consistently high
levels (> 80%) of growth inhibition in vitro [30,31] and
much attention has focused on this protein as a promis-
ing vaccine candidate against malaria. In contrast, anti-
MSP119 antibodies show more moderate inhibitory
activity [29,32,33]. If growth inhibitory activity is suffi-
cient for protection, then an effective malaria blood-
stage vaccine would likely need to be made up of multi-
ple antigens. Growth inhibition leading to decreased
replication through the erythrocytic cycle is likely to be
a result of the collective immunogenic ability of the
multiple antigens. On this basis a growth inhibitory
capacity of 40% observed for MSP4 as a single antigen
would be a significant contribution. Further studies are
required to determine if the level of growth inhibition is
increased when antibodies directed to several merozoite
surface antigens are tested in combination.
Despite extensive work the value of using GIA as the
sole correlate of immune protection from Plasmodium
infections is still unclear. The validity of this in vitro
assay may be confirmed once vaccine trials are carried
out in humans and in vitro inhibition is shown to corre-
late with in vivo protection. A recent Phase IIa trial of
AMA-1 has shown disappointing results in this regard
[34]. Antibodies classically act in conjunction with other
mechanisms of immunity, such as complement mediated
destruction of the pathogen and enhanced phagocytic
activity mediated by antibody opsonization. These
mechanisms are also likely to be operating in immunity
to blood stage malaria. Interestingly, the majority of
human antibodies recognizing MSP4 were of the IgG3
and IgG1 isotypes suggesting that they may play a role
in opsonization and complement-mediated destruction
of free merozoites [6].
The Antibody Dependent Cellular Inhibition or Cyto-
toxicity assay (ADCI or ADCC) is another in vitro assay
that can be used to determine antibody efficacy in co-
operation with monocytes to limit P. falciparum growth
[35,36]. Interestingly, a positive ADCI has been demon-
strated for other blood stage antigens MSP3 [37] and
GLURP [38], despite the lack of in vitro growth inhibi-
tion by antibodies alone. In view of this finding, our
antisera raised against MSP4 are currently being tested
for ADCI activity.
Apart from antibody-mediated immunity, cellular
mechanisms such as the production of IFNg-producing
T cells are also important in mediating protection
against blood stage malaria [39,40]. T cells that recog-
nize dominant epitopes in vaccine proteins are essential
for long-term protection against malaria in animal mod-
els. Preliminary work was carried out to predict the pos-
sible T cell epitopes of MSP4 in humans that bind
across diverse HLA molecules using an epitope predic-
tion algorithm [41]. All four regions of the molecule
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topes and these areas also overlapped with the three
peptides containing B cell epitopes. These findings have
important implications for vaccine design enabling
incorporation of peptide antigens that are able to stimu-
late strong T and B cell responses to MSP4.
Conclusions
A panel of Mabs specific for P. falciparum MSP4 were
generated, characterized and used to develop an MSP4-
specific competition ELISA to test antibody specificity in
sera from naturally infected individuals. All epitopes
recognized by the Mabs were readily recognized by
human immune sera, with heterogeneity in the intensity
of the humoral response among different individuals.
Growth inhibition assays were carried out comparing
growth inhibitory activity of the Mabs and polyclonal
rabbit sera. The results demonstrate that multiple MSP4
epitopes spanning the entire protein need to be targeted
to significantly inhibit P. falciparum growth. These find-
ings provide insight into the MSP4 specific antibody
response and have important implications for the design
of blood stage vaccines.
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